Invention Grant
- Patent Title: Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity
-
Application No.: US17106928Application Date: 2020-11-30
-
Publication No.: US11638751B2Publication Date: 2023-05-02
- Inventor: Sylvain Baize , Audrey Page , Xavier Carnec , Mathieu Jean Simon Mateo , Stephanie Reynard , Alexandra Fizet
- Applicant: INSTITUT PASTEUR
- Applicant Address: FR Paris
- Assignee: INSTITUT PASTEUR
- Current Assignee: INSTITUT PASTEUR
- Current Assignee Address: FR Paris
- Agency: Arrigo, Lee, Guttman & Mouta-Bellum LLP
- Main IPC: A61K39/12
- IPC: A61K39/12 ; C12N7/00 ; C12N9/16 ; A61K39/00 ; C12N9/22
Abstract:
A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
Public/Granted literature
- US20210205436A1 RECOMBINANT MOPEIA VIRUS AND VACCINE PLATFORM Public/Granted day:2021-07-08
Information query
